Open letter re: Urgent need to register essential medicines for the treatment and prevention of tuberculosis (TB) in South Africa

Dear Dr. Nkambule and colleagues,

We welcome the establishment of South African Health Products Regulatory Authority (SAHPRA) as an advance to ensure transparent, efficient, and effective regulation of health products and research in South Africa. However, we are concerned that access to essential medicines and initiation of vital research remain delayed due to regulatory processes. In particular, we request your attention to ensure availability of and timely research into new prevention and treatment options, for tuberculosis (TB), which despite being preventable and curable, remains the leading cause of death in South Africa. Namely, we request your attention to 1) marketing approval of, and expedition of further research into, delamanid, an important medicine for treating drug-resistant strains of TB; 2) approval of rifapentine, which allows for dramatic shortening of preventive therapy for TB; and 3) approval of child-friendly formulations of TB medicines, which facilitate dosing and ease the burden of TB treatment on children and those administering treatment alike.

1) Approving delamanid and expediting further research
South African civil society and the global TB response community heralded South Africa’s leadership in being the first country to scale up use of bedaquiline, one of only two new drugs developed for treating drug-resistant TB. Yet South Africa is lagging on utilizing the other drug, delamanid. Delamanid has been approved by the European Medicines Agency since 2014 and is recommended by the World Health Organization (WHO) for use in people with rifampicin-resistant TB as young as six years. It has been tested in randomized clinical trials—more than can be said for most other drugs currently used in South Africa and globally to treat drug-
resistant TB—and has been found to be safe, well-tolerated, and have no clinically significant interactions with antiretrovirals. Delamanid is an essential drug (indeed, it is on the WHO Model Lists of Essential Medicines for both adults and children) for treating drug-resistant TB, especially in those for whom a robust regimen cannot otherwise be constructed.

Approving delamanid will enable South Africans affected by TB to benefit from South Africa’s bold and wise decision to move towards injectable-free regimens. Given its safety and tolerability relative to other TB drugs with even less evidence of efficacy, delamanid also has an essential role to play as a component of a robust regimen for adults with drug-resistant TB, and warrants approval. We need all the tools at our disposal to fight the TB epidemic, to ensure all persons with TB are given the best chance at a full cure.

We also encourage SAHPRA to rapidly review and approve research proposals that test novel drug candidates and/or regimens for TB. From early-stage monotherapy and early bactericidal activity studies of new investigational agents through late-stage trials to optimize regimens and shorten treatment, well-designed clinical trials in TB are urgently needed.

2) Approving rifapentine
TB is not only curable but preventable. With its large burden of people at high risk for developing active TB—including people with HIV, close contacts of people with TB, clinicians, and miners—South Africa would benefit greatly from more prevention options. Rifapentine is an important product for preventing TB, as it reduces the length of TB preventive therapy from nine months of daily therapy to just 12 once-weekly doses (and new research indicates rifapentine can further shorten TB preventive therapy to just one month of daily dosing).

We appreciate the fast track review was granted to rifapentine, and are aware that SAHPRA has sent questions to the applicant Sanofi. We hope that, pending Sanofi's submission of its answers, the review can proceed with all due acceleration to allow for approval within this calendar year, thus facilitating use of the product starting in 2019. After being approved for active TB for decades, rifapentine received U.S. Food and Drug Administration approval for an indication for treatment of latent TB infection in 2014. Rifapentine is also approved for preventive therapy by regulatory authorities of the Philippines, Hong Kong, and Taiwan. We hope South Africa can soon follow suit.

We understand Sanofi in process of making required updates to its chemistry, manufacturing, and control (CMC) dossier, and in several countries approval was granted on the condition of approval of updates being entered at a later date. Similar arrangements should be possible for South Africa, if this is contributing to the delay in the product’s approval.

3) Approving paediatric formulations of TB medicines
Children are particularly vulnerable to TB. To facilitate TB treatment in children, there is an urgent need for SAHPRA to approve the paediatric fixed dose combinations and reformulated stand-alone dispersible tablets of first-line drugs and to allow the importation of dispersible tablets of second-line TB medicines so that acceptability can be confirmed and a long-term access plan can be developed. While these first- and second-line TB medicines have been approved and available for use in South Africa for decades, they are inappropriately dosed and
formulated for children, requiring higher pill burdens and crushing and splitting tablets to approximate correct dosages. Fixed-dose dispersible combinations and stand-alone dispersible tablets of these same medicines, developed by Macleods, facilitate administration and accurate dosing, reduce pill burden, and improve taste and acceptability for children, easing the difficulties of TB treatment for children and those who care for them. We look forward to these formulations, some of which have been available on the global market since 2015, being available to South African children.

Finally, we request SAHPRA to make its decision-making processes about health products, including but not limited to, TB, transparent and have a venue for input from affected communities such as those we represent.

We hope to see the registration of delamanid, rifapentine, and the paediatric formulations of first- and second-line TB medicines shortly, as well as the continuation of high quality TB research in South Africa. We appreciate your consideration of our letter, and look forward to your response, which can be directed to Lindsay McKenna, lindsay.mckenna@treatmentactiongroup.org and Ingrid Schoeman, Ingrid.tbproof@gmail.com by 5 September 2018.

Respectfully submitted,
On behalf of the undersigned organizations and individuals

Organizations
Activists Coalition on TB - Asia Pacific (ACT! AP), Asia Pacific
AIDS Foundation East West (AFEW International), The Netherlands
Alliance for Public Health, Ukraine
Desmond Tutu TB Centre, South Africa
Drug Resistant Tuberculosis Treatment Action Team (DR-TB STAT), USA
Eurasian Harm Reduction Association (EHRA), Lithuania
European AIDS Treatment Group, Belgium
Global Coalition of TB Activists (GCTA), Global TB Community Advisory Board (TB CAB), Global
HAYAT, National Humanitarian Public Union, Azerbaijan
 Médecins Sans Frontières (MSF) South Africa, South Africa
Norwegian Heart and Lung Patient Organisation (LHL International), Norway
Romanian Angel Appeal Foundation, Romania
Saglamliga Khidmat, Azerbaijan
School of Public Health & Family Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
Sentinel Project on Pediatric Drug Resistant Tuberculosis, USA
 Southern African HIV Clinicians Society, South Africa
Speranta terrei, Moldova
Stop Stockouts Project, South Africa
Support of people living with HIV Kuat, Kazakhstan
TB Europe Coalition, Regional network of Eastern and Western Europe, Caucuses and Central Asia
TB Proof, South Africa
Treatment Action Campaign (TAC), South Africa
Treatment Action Group (TAG), USA
WACI Health, South Africa

**Individuals**
Andrea von Delft, TB Proof, South Africa
Andreas Diacon, Founder, Director and CEO Task Applied Science, South Africa
Arne von Delft, University of Cape Town (UCT) School of Public Health & Family Medicine and TB Proof, Living with presumed latent MDR-TB, South Africa
Bavashnee Chetty, Medical doctor, Western Cape, South Africa
Carole D. Mitnick, Sc.D., Associate Professor, Department of Global Health & Social Medicine, Harvard Medical School, Boston, USA
Colleen Daniels, CD Global Consulting, South Africa
Daisy Dharmaraj, TEST Foundation, Chennai, India
Dalene von Delft, Occupational MDR-TB survivor, TB Proof, South Africa
Enock Havyarimana, Division of Immunology, School of Public Health and Family Medicine, UCT, South Africa
Faghmeda Miller, HIV AIDS activist, National Association of People Living with HIV and AIDS (NAPWA), Cape Town, South Africa
Fareed Abdullah, Director: Office of AIDS and TB Research, South African Medical Research Council (SA MRC), Pretoria, South Africa
Francis George Apina, COPFAM, Suna - Migori, Kenya
Gimenne Zwama, Institute for Global Health and Development, Queen Margaret University and School of Public Health and Nursing, University of KwaZulu-Natal, Scotland/South Africa
Heena Narotam, medical doctor, TB Proof, Worcester, South Africa
Ingrid Schoeman, Registered Dietitian, Pre-XDR TB Survivor, TB Proof, Pretoria, South Africa
Jackie Mondi, Student, Wits University, Johannesburg, South Africa
Jennifer Furin, Harvard Medical School, Department of Global Health & Social Medicine, Boston, MA, USA
Jeroen van Gorkom, KNCV Tuberculosis Foundation, The Netherlands
Judy Caldwell, TB Programme Manager, City of Cape Town, South Africa
Lauren Jankelowitz, The Southern African HIV Clinicians Society, South Africa
Leslie London, School of Public Health, UCT, South Africa
Marion Heap, Health and Human Rights Programme, Division of Public Health Medicine, School of Public Health and Family Medicine, UCT, South Africa.
Martie van der Walt, Director: SA MRC, Tuberculosis Platform, Pretoria, South Africa
Mary E Miller, School of Public Health and Family Medicine, UCT, South Africa
Maryam Bibi Rumane, Maryam Rumaney, South Africa
Nesi Padayatchi, Clinician /scientist, South Africa
Noluvo Ngambu, Healthcare Worker, TB CMO, Cape Town, South Africa
Paul Nunn, Director, Global Infectious Diseases Consulting Ltd, London, United Kingdom
Salome Charalambous, Department: Research Management, Implementation Research, The Aurum Institute, Parktown, South Africa.
Shehani Perera, UCT, Malawi
Thato Mosidi, Medical Doctor and XDR TB Survivor, TB Proof, Cape Town, South Africa
Vela Mhlola, TASK Applied Science, South Africa
Warick Van Der Lingen, Community Service Dietitian, South Africa
Wieda Human, Registered Dietitian, TB Proof, Bloemfontein, South Africa
Wim Vandevelde, Global TB CAB, Cape Town, South Africa
Zara Trafford, School of Public Health & Family Medicine, UCT, South Africa